Wenjie J. Xiong

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020
Tianjin, 301600, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma

Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.

MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.

Journal: Leukemia

Published: December 10, 2025

The prognostic implications of autoimmune hemolytic anemia in chronic lymphocytic leukemia across treatment eras.

The prognostic implications of autoimmune hemolytic anemia in chronic lymphocytic leukemia across treatment eras.

Journal: Haematologica

Published: October 28, 2025

Proteogenomic features define subtypes of mantle cell lymphoma.

Proteogenomic features define subtypes of mantle cell lymphoma.

Journal: Blood advances

Published: October 09, 2025

Proteogenomic features define subtypes of mantle cell lymphoma.

Proteogenomic features define subtypes of mantle cell lymphoma.

Journal: Blood advances

Published: October 09, 2025

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Journal: EClinicalMedicine

Published: August 15, 2025

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.

Journal: Leukemia

Published: August 10, 2025

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

Journal: MedScience

Published: August 06, 2025

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Journal: Blood advances

Published: May 07, 2025

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal

Published: May 06, 2025

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal

Published: May 06, 2025

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Journal: The oncologist

Published: April 01, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026